A Phase 2 Study Of BAY 43-9006 [sorafenib] In Combination With Interferon Alfa-2b In Metastatic Renal Cell Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2013
At a glance
- Drugs Interferon alpha-2b (Primary) ; Sorafenib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Aug 2009 Additional lead trial investigator (Daniel J. George) identified as reported by ClinicalTrials.gov.
- 06 Aug 2005 New trial record.